Antirheumatic Drugs in Pregnancy and Lactation

Temprano, Katherine; Bandlamudi, Rama; Moore, Terry L.

doi:10.1016/j.semarthrit.2005.05.002

Cited by 124 publications

(77 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[56][57][58] In these reports the administration of rituximab in pregnancy, including during the first trimester, was not associated with an increased risk of adverse fetal outcome. A recent report of a 35-year old pregnant woman, treated with rituximab and CHOP therapy early during pregnancy, described transient complete fetal B-cell depletion associated with high rituximab cord blood concentrations.…”

Section: © F E R R a T A S T O R T I F O U N D A T I O Nmentioning

confidence: 87%

The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy

Pereg

Koren²,

Lishner³

2007

Haematologica

117

View full text Add to dashboard Cite

Lymphoma is the fourth most frequent malignancy diagnosed during pregnancy, occurring in approximately 1:6000 of deliveries. Its occurrence may increase due to the current trend to postpone pregnancy until later in life and the suggested high incidence of AIDS-related non-Hodgkin's lymphoma in developing countries. The relatively rare occurrence of pregnancy-associated lymphoma precludes the conduction of large, prospective studies to examine diagnostic, management and outcome issues. Chemotherapy and radiotherapy during the first trimester are associated with increased risk of congenital malformations and this risk diminishes as pregnancy advances. In the vast majority of cases, when lymphoma is diagnosed during the first trimester, treatment with a standard chemotherapy regimen, following pregnancy termination should be recommended. In the rare patients at low risk, such as those with stage 1 Hodgkin's lymphoma or indolent non-Hodgkin's lymphoma, therapy can be delayed until the end of the first trimester and of embryogenesis while keeping the patients under close observation. When lymphoma is diagnosed during the second and third trimesters, evidence exists suggesting that full-dose chemotherapy can be administered safely without apparent increased risk of severe adverse fetal outcome.

show abstract

Section: © F E R R a T A S T O R T I F O U N D A T I O Nmentioning

confidence: 87%

The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy

Pereg

Koren²,

Lishner³

2007

Haematologica

117

View full text Add to dashboard Cite

show abstract

“…As a result of embryotoxic and teratogenic effects, MTX is discontinued in women planning to conceive 2,3,4 . RA disease activity often decreases during pregnancy and increases after delivery 5 .…”

Section: To the Editormentioning

confidence: 99%

Methotrexate Use in a Breastfeeding Patient with Rheumatoid Arthritis

Nadarajah

Moretti

et al. 2014

J Rheumatol

View full text Add to dashboard Cite

“…18,19 Given the teratogenicity associated with MMF, most rheumatologist and nephrologists would change to azathioprine or other agents, such as hydroxychloroquine and sulfasalazine, as necessary for maintenance or treatment in the setting of pregnancy. 20 In addition, long-term follow-up of younger patients is crucial, as some patients treated with gonadotoxic agents with previously normal ovarian function have been found to experience early menopause. 19,21 Risk factors for POI secondary to cyclophosphamide therapy include age, cumulative dose, history of thyroid disease, disease duration, and the presence of anti-Ro and anti-U1RNP antibodies.…”

Section: Autoimmune Diseases Treated With Gonadotoxic Therapiesmentioning

confidence: 99%

Nonmalignant Diseases and Treatments Associated with Primary Ovarian Failure: An Expanded Role for Fertility Preservation

Hirshfeld-Cytron

Gracia

Woodruff

2011

Journal of Women's Health

View full text Add to dashboard Cite

Cancer treatments can be detrimental to fertility; recent literature has focused on the efforts of fertility preservation for this patient population. It should be recognized, however, that several nonmalignant medical conditions and therapeutic interventions could be similarly hazardous to fertility. Some of these nonmalignant diseases and their treatments that can adversely impact the reproductive axis are gastrointestinal diseases, rheumatologic disorders, nonmalignant hematologic conditions, neurologic disorders, renal disorders, gynecologic conditions, and metabolic diseases. Their negative effects on reproductive function are only now being appreciated and include impaired ovarian function, endocrine function, or sexual function and inability to carry a pregnancy to term. Complications and comorbidities associated with certain diseases may limit the success of established fertility preservation options. Recent advances in fertility preservation techniques may provide these patients with new options for childbearing. Here, we review several fertility-threatening conditions and treatments, describe current established and experimental fertility preservation options, and present three initiatives that may help minimize the adverse reproductive effects of these medical conditions and treatments by raising awareness of the issues and options: (1) increase awareness among practitioners about the reproductive consequences of specific diseases and treatments, (2) facilitate referral of patients to fertility-sparing or restorative programs, and (3) provide patient education about the risk of infertility at the time of diagnosis before initiation of treatment.

show abstract

Antirheumatic Drugs in Pregnancy and Lactation

Cited by 124 publications

References 60 publications

The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy

The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy

Methotrexate Use in a Breastfeeding Patient with Rheumatoid Arthritis

Nonmalignant Diseases and Treatments Associated with Primary Ovarian Failure: An Expanded Role for Fertility Preservation

Contact Info

Product

Resources

About